Back to News
Market Impact: 0.2
HC Wainwright & Co. initiates coverage of Lakewood-Amedex Biotherapeutics with Buy rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 28, 2026, HC Wainwright & Co. initiated coverage of Lakewood-Amedex Biotherapeutics (NASDAQCM: LABT) with a Buy recommendation. The article identifies this as the company's primary analyst activity that day; no price target or market reaction is provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LABT0.55
More News
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Intel plunges on a major guidance miss. What went wrong — and how to proceed
- FedEx Freight delivers a much-needed quarterly beat. Where we stand on shares now
- We're cutting our Amazon price target after a tough quarter. But it isn't all bad
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps